<?xml version='1.0' encoding='utf-8'?>
<document id="30428505"><sentence text="Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies." /><sentence text="Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies"><entity charOffset="0-9" id="DDI-PubMed.30428505.s2.e0" text="Oprozomib" /></sentence><sentence text=" Oprozomib is a rare example of a small molecule drug that demonstrates cytochrome P450 (CYP) mRNA suppression"><entity charOffset="1-10" id="DDI-PubMed.30428505.s3.e0" text="Oprozomib" /></sentence><sentence text=" This unusual property elicits uncertainty regarding the optimal approach for predicting its drug-drug interaction (DDI) risk" /><sentence text=" The current study aims to understand DDI potential during early clinical development of oprozomib" /><sentence text="" /><sentence text="To support early development of oprozomib (e"><entity charOffset="32-41" id="DDI-PubMed.30428505.s7.e0" text="oprozomib" /></sentence><sentence text="g" /><sentence text=" inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential" /><sentence text=" Subsequently, a clinical DDI study using midazolam as the substrate was conducted in patients with advanced malignancies"><entity charOffset="42-51" id="DDI-PubMed.30428505.s10.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="The clinical DDI study enrolled a total of 21 patients, 18 with advanced solid tumours" /><sentence text=" No patient discontinued oprozomib due to a treatment-related adverse event" /><sentence text=" The PBPK model prospectively predicted oprozomib 300 mg would not cause a clinically relevant change in exposure to CYP3A4 substrates (≤30%), which was confirmed by the results of this clinical DDI study"><entity charOffset="40-49" id="DDI-PubMed.30428505.s14.e0" text="oprozomib" /></sentence><sentence text="" /><sentence text="These results indicate oprozomib has a low potential to inhibit the metabolism of CYP3A4 substrates in humans"><entity charOffset="23-32" id="DDI-PubMed.30428505.s16.e0" text="oprozomib" /></sentence><sentence text=" The study shows that cultured human hepatocytes are a more reliable system for DDI prediction than human liver microsomes for studying this class of compounds" /><sentence text=" Developing a PBPK model prior to a clinical DDI study has been valuable in supporting clinical development of oprozomib" /><sentence text="" /></document>